Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mometasone Furoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | CNR1 | P21554 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mometasone Furoate SCHEMBL8826257 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL7436523 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL2594997 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL13026146 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL4568 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL600107 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL25382496 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL12996648 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL8430908 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL4484 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | NXP B.V. (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-0292893-A1 | Steroid lotion | SCHERING CORPORATION (US) | 1988-11-30 | — | — | EP | disclosed |
| US-4775529-A | ANTIINFLAMMATORY, VASOCONSTRICTION; PROPYLENE GLYCOL; ISOPROPANOL AND THICKENER; SKIN DISORDERS | SCHERING CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | MC2R, GALR3, CHRM3 | NR3C1 10/4885CYP3A4 903/4885LMNA 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.